Cone-Rod dystrophy – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Cone-rod dystrophy is a group of related
eye disorders that causes vision loss, which becomes more severe over time.
These disorders affect the retina, which is the layer of light-sensitive tissue
at the back of the eye. In people with cone-rod dystrophy, vision loss occurs
as the light-sensing cells of the retina gradually deteriorate. The cone cells
are initially involved, as previously mentioned, and difficulty with the
clarity of vision, color vision problems, and light sensitivity can be some of
the earliest symptoms experienced. This is followed by a progressive loss of
rod cells, which leads to night blindness and loss of side vision. The first
signs and symptoms of cone-rod dystrophy, which often occur in childhood, are
usually decreased sharpness of vision (visual acuity) and increased sensitivity
to light (photophobia). Mutations in the ABCA4 gene are the most common cause
of autosomal recessive cone-rod dystrophy, accounting for 30 to 60 percent of
cases. At least 10 genes have been associated with cone-rod dystrophy that is
inherited in an autosomal dominant pattern. Mutations in the GUCY2D and CRX
genes account for about half of these cases. Changes in at least two genes
cause the X-linked form of the disorder, which is rare.
The incidence of Cone-rod dystrophy is
estimated to be 1 to 1.5 cases in 50,000 individuals in the USA.
The competitive
landscape of Cone-Rod dystrophy includes country-specific approved and pipeline
therapies. Any asset/product-specific designation or review and Accelerated
Approval are tracked and supplemented with analyst commentary.
KOLs insights of Cone-Rod
dystrophy across 8 MM market from the center of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Cone-Rod
dystrophy Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 VAR002 Variant
Bio -
2 rhNGF Dompé
Farmaceutici S.p.A Phase 2
Comments
Post a Comment